Efficacy of a combined oral clindamycin–rifampicin regimen for therapy of staphylococcal osteoarticular infections

References

• Uçkay I, Laurent F, Lustig S, Rasigade, JP, Thompson V, Paoli V, . Hospital and community-acquired methicillin-resistant Staphylococcus aureus bone and joint infections. Charles L. Kolendi. New York: Nova Science Publishers; 2009. 143–209.
   Google Scholar
• Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645–54.
   PubMed Web of Science ®Google Scholar
• Uçkay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F. Foreign body infections due to Staphylococcus epidermidis. Ann Med 2009;41:109–19.
   PubMed Web of Science ®Google Scholar
• Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364: 369–79.
   PubMed Web of Science ®Google Scholar
• Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 2006;66: 1089–105.
   PubMed Web of Science ®Google Scholar
• Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med 2009;361:787–94.
   PubMed Web of Science ®Google Scholar
• Uçkay I, Lew D. Infections in skeletal prostheses. William R. Jarvis. Bennet & Brachman's hospital infections. 5th. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007. 665–72.
   Google Scholar
• Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008;168:805–19.
   PubMedGoogle Scholar
• Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986;29:611–3.
   PubMed Web of Science ®Google Scholar
• Arditi M, Yogev R. In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. Antimicrob Agents Chemother 1989;33:245–7.
   PubMed Web of Science ®Google Scholar
• Feigin RD, Pickering LK, Anderson D, Keeney RE, Shackleford PG. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics 1975;55:213–23.
   PubMed Web of Science ®Google Scholar
• El Samad Y, Havet E, Bentayeb H, Olory B, Canarelli B, Lardanchet JF, . Treatment of osteoarticular infections with clindamycin in adults. Med Mal Infect 2008;38: 465–70.
   PubMed Web of Science ®Google Scholar
• Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010;54:88–92.
   PubMed Web of Science ®Google Scholar
• Ho JL, Klempner MS. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis 1986;4:133–8.
   PubMed Web of Science ®Google Scholar
• Renneberg J, Karlsson E, Nilsson B, Walder M. Interactions of drugs acting against Staphylococcus aureus in vitro and in a mouse model. J Infect 1993;26:265–77.
   PubMed Web of Science ®Google Scholar
• O’Reilly T, Kunz S, Sande E, Zak O, Sande MA, Täuber MG. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. Antimicrob Agents Chemother 1992;36:2693–7.
   PubMed Web of Science ®Google Scholar
• Phillips I. Clinical uses and control of rifampicin and clindamycin. J Clin Pathol 1971;24:410–8.
   PubMed Web of Science ®Google Scholar
• Dhawan VK, Thadepalli H. Clindamycin: a review of fifteen years of experience. Rev Infect Dis 1982;4:1133–53.
   PubMedGoogle Scholar
• Srinivasan S, Sheela D, Mathew R, Bazroy J, Kanungo R. Risk factors and associated problems in the management of infections with methicillin-resistant Staphylococcus aureus. Indian J Med Microbiol 2006;24:182–5.
   PubMedGoogle Scholar
• Mitchell PD, Hunt DM, Lyall H, Nolan M, Tudor-Williams G. Panton–Valentine leukocidin-secreting Staphylococcus aureus causing severe musculoskeletal sepsis in children. A new threat. J Bone Joint Surg 2007;89:1239–42.
   Google Scholar
• Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, . Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009;219:148–54.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143–7.
   PubMed Web of Science ®Google Scholar
• François P, Harbarth S, Huyghe A, Renzi G, Bento M, Gervaix A, . Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993–2005. Emerg Infect Dis 2008; 14:304–7.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 17^th Informational supplement. M100–S17. Wayne PA: CLSI; 2007.
   Google Scholar
• Svensson E, Hanberger H, Nilsson LE. Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells. Antimicrob Agents Chemother 1997;41:107–11.
   PubMed Web of Science ®Google Scholar
• Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using E-test and with a focus on rifampicin and linezolid. Eur J Clin Microbiol Infect Dis 2010; 29:591–5.
   PubMed Web of Science ®Google Scholar
• Soriano A, Gómez J, Gómez L, Azanza JR, Pérez R, Romero F, . Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007;26:353–6.
   PubMed Web of Science ®Google Scholar
• Berdal JE, Skråmm I, Mowinckel P, Gulbrandsen P, Bjørnholt JV. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect 2005;11:843–5.
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 1998;279:1537–41.
   PubMed Web of Science ®Google Scholar
• Soriano A, García S, Bori G, Almela M, Gallart X, Macule F, . Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect 2006;12:930–3.
   PubMed Web of Science ®Google Scholar
• Aboltins CA, Page MA, Buising KL, Jenney AW, Daffy JR, Choong PF, . Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13:586–91.
   PubMed Web of Science ®Google Scholar
• Antony SJ. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2006;38:293–5.
   PubMed Web of Science ®Google Scholar
• Burns CA. Daptomycin–rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 2006;38:133–6.
   PubMed Web of Science ®Google Scholar
• Gagnon RF, Richards GK, Kostiner GB. Time-kill efficacy of antibiotics in combination with rifampin against Staphylococcus epidermidis biofilms. Adv Perit Dial 1994;10:189–92.
   PubMedGoogle Scholar
• Uçkay I, Assal M, Legout L, Rohner P, Stern R, Lew D, . Recurrent osteomyelitis caused by infection with different bacterial strains without obvious source of reinfection. J Clin Microbiol 2006;44:1194–6.
   PubMed Web of Science ®Google Scholar